Acelyrin, Inc. (NASDAQ:SLRN) Shares Sold by Los Angeles Capital Management LLC

Los Angeles Capital Management LLC lowered its stake in Acelyrin, Inc. (NASDAQ:SLRN) by 14.5% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 122,003 shares of the company’s stock after selling 20,690 shares during the quarter. Los Angeles Capital Management LLC owned about 0.12% of Acelyrin worth $383,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of the stock. Geode Capital Management LLC lifted its holdings in shares of Acelyrin by 30.8% in the 3rd quarter. Geode Capital Management LLC now owns 1,651,614 shares of the company’s stock worth $8,144,000 after acquiring an additional 388,631 shares during the last quarter. Acuta Capital Partners LLC purchased a new stake in Acelyrin in the third quarter valued at approximately $1,795,000. Charles Schwab Investment Management Inc. lifted its stake in Acelyrin by 81.4% during the third quarter. Charles Schwab Investment Management Inc. now owns 609,678 shares of the company’s stock worth $3,006,000 after purchasing an additional 273,604 shares in the last quarter. Point72 Asset Management L.P. boosted its position in shares of Acelyrin by 566.7% during the third quarter. Point72 Asset Management L.P. now owns 250,300 shares of the company’s stock worth $1,234,000 after buying an additional 212,758 shares during the period. Finally, State Street Corp boosted its position in shares of Acelyrin by 10.0% during the third quarter. State Street Corp now owns 1,273,096 shares of the company’s stock worth $6,276,000 after buying an additional 116,094 shares during the period. Hedge funds and other institutional investors own 87.31% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on SLRN shares. Wells Fargo & Company decreased their target price on Acelyrin from $15.00 to $13.00 and set an “overweight” rating on the stock in a research note on Wednesday, December 11th. HC Wainwright cut their price target on shares of Acelyrin from $8.00 to $6.00 and set a “neutral” rating on the stock in a research note on Tuesday, January 7th. Finally, Citigroup lowered their price objective on shares of Acelyrin from $6.00 to $3.00 and set a “neutral” rating for the company in a research note on Tuesday, January 7th. Three analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $9.60.

Acelyrin Price Performance

SLRN opened at $2.69 on Tuesday. The business has a fifty day moving average price of $2.36 and a 200 day moving average price of $4.00. Acelyrin, Inc. has a 12 month low of $1.85 and a 12 month high of $8.76. The stock has a market capitalization of $269.88 million, a price-to-earnings ratio of -1.09 and a beta of 1.85.

About Acelyrin

Acelyrin, Inc, a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis.